Gsk (GLAXF) Common Equity (2016 - 2025)
Historic Common Equity for Gsk (GLAXF) over the last 17 years, with Q3 2025 value amounting to $21.3 billion.
- Gsk's Common Equity rose 2157.22% to $21.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $21.3 billion, marking a year-over-year increase of 2157.22%. This contributed to the annual value of $16.7 billion for FY2024, which is 76.02% up from last year.
- Latest data reveals that Gsk reported Common Equity of $21.3 billion as of Q3 2025, which was up 2157.22% from $19.1 billion recorded in Q2 2025.
- In the past 5 years, Gsk's Common Equity ranged from a high of $36.0 billion in Q1 2022 and a low of $10.3 billion during Q3 2022
- Its 5-year average for Common Equity is $20.2 billion, with a median of $17.4 billion in 2024.
- Per our database at Business Quant, Gsk's Common Equity plummeted by 6573.8% in 2022 and then soared by 5560.69% in 2023.
- Quarter analysis of 5 years shows Gsk's Common Equity stood at $20.3 billion in 2021, then tumbled by 38.75% to $12.4 billion in 2022, then surged by 33.26% to $16.6 billion in 2023, then increased by 1.39% to $16.8 billion in 2024, then increased by 26.52% to $21.3 billion in 2025.
- Its Common Equity stands at $21.3 billion for Q3 2025, versus $19.1 billion for Q2 2025 and $17.2 billion for Q1 2025.